Cybin to participate in the 2025 psychedelic science conference

Toronto--(business wire)--cybin inc. (nyse american:cybn) (cboe ca:cybn) (“cybin” or the “company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that doug drysdale, cybin's chief executive officer, will be speaking at the psychedelic science 2025 conference taking place june 16-20, 2025 in denver, colorado. the details are as follows: panel title: t.
CYBN Ratings Summary
CYBN Quant Ranking